Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Protagonist Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses in Focus

In the world of pharmaceuticals, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two industry players: Pfizer Inc. and Protagonist Therapeutics, Inc., from 2014 to 2023. Pfizer, a giant in the pharmaceutical industry, consistently reported SG&A expenses averaging around $14 billion annually. In contrast, Protagonist Therapeutics, a smaller biotech firm, showed a steady increase in SG&A expenses, growing from $1.9 million in 2014 to $33.5 million in 2023, a staggering 17-fold increase.

This stark contrast highlights the scale and operational strategies of these companies. While Pfizer's expenses reflect its vast global operations, Protagonist's growth in SG&A expenses underscores its expanding footprint in the biotech sector. This comparison offers a fascinating glimpse into how different companies manage their operational costs in a competitive industry.